Boston Scientific Shares Rise on Q1 Earnings Beat and Revised Guidance
Boston Scientific (BSX) shares surged 9.16% following its Q1 earnings beat and a reduction in 2026 sales growth guidance. The stock's performance outpaced its medical device peers, despite the lowered guidance, as investors reassessed growth expectations. The S&P 500 and Nasdaq Composite also rose, with the Nasdaq gaining 1.64%.
Topics: Earnings Beat Guidance Adjustment Investor Reaction Medical Devices Stock Performance